Elesclomol is an anticancer drug that targets mitochondrial metabolism. In the past,
elesclomol was recognized as an inducer of oxidative stress, but now it has also been found …

The successful treatment of cancer has significantly improved as a result of targeted therapy
and immunotherapy. However, during chemotherapy, cancer cells evolve and can acquire …

Mitochondrial metabolism must constantly adapt to stress conditions in order to maintain
bioenergetic levels related to cellular functions. This absence of proper adaptation can be …

Pharmacological ascorbate has been proposed as a potential anti-cancer agent when
combined with radiation and chemotherapy. The anti-cancer effects of ascorbate are …

Summary BRAF (V600E) mutant melanomas treated with inhibitors of the BRAF and MEK
kinases almost invariably develop resistance that is frequently caused by reactivation of the …

Resistance to therapeutic agents, either intrinsic or acquired, is currently a major problem in
the treatment of cancers and occurs in virtually every type of anti-cancer therapy. Therefore …

Cuproptosis is a newly identified form of cell death driven by copper. Recently, the role of
copper and copper triggered cell death in the pathogenesis of cancers have attracted …

Cancer is a disease of ageing. Clinically, aged cancer patients tend to have a poorer
prognosis than young. This may be due to accumulated cellular damage, decreases in …

Melanoma is the most lethal form of skin cancer. Melanoma is usually curable with surgery if
detected early, however, treatment options for patients with metastatic melanoma are limited …

Simple Summary Patients with advanced melanoma are often treated with v-raf murine
sarcoma viral oncogene homolog B1 (BRAF) inhibitors. Although these agents prolong life …